NE

New Frontier Minerals Limited

Mineral explorer of rare earths, niobium, uranium, and copper assets in Australia and Zambia.

NFM | IL

Overview

Corporate Details

ISIN(s):
AU0000368748
LEI:
213800AG47SZ4DGATD33
Country:
Australia
Address:
45 VENTNOR AVENUE, 6005 WEST PERTH
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

New Frontier Minerals Limited is a mineral exploration company focused on identifying and developing multi-commodity assets with the potential for economic mining operations. The company applies a disciplined and structured exploration strategy to advance its projects. Its portfolio includes assets in Australia and Zambia, with exploration focused on commodities such as heavy rare earths, niobium, uranium, and copper. A key area of current activity is the Harts Range Heavy Rare Earths and Niobium Project in Australia's Northern Territory.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 08:25
Regulatory News Service
Mining Lease Application at Big One Copper Deposit
English 25.8 KB
2025-11-10 08:10
Regulatory News Service
Drilling Campaign Approved at Harts Range Project
English 21.9 KB
2025-11-03 19:46
Regulatory News Service
Drill Targets Finalised at Harts Range Project
English 21.9 KB
2025-10-31 11:28
Pre-Annual General Meeting Information
Addendum to Notice of Annual General Meeting
English 25.2 KB
2025-10-29 11:54
Pre-Annual General Meeting Information
AGM Date & Closing Date for Director Nominations
English 12.7 KB
2025-10-09 08:00
Pre-Annual General Meeting Information
Notice of AGM
English 14.0 KB
2025-09-22 08:00
Annual Report
Final Results and Publication of Annual Report
English 615.1 KB
2025-09-22 08:00
Governance Information
Appendix G4 and Corporate Governance Statement
English 14.4 KB
2025-09-17 09:22
Delisting Announcement
Notification of Cessation of Securities
English 18.7 KB
2025-09-11 08:00
Regulatory News Service
Appointment of Drill Contractor
English 26.8 KB
2025-08-26 08:00
Report Publication Announcement
Appendix 3G
English 10.7 KB
2025-08-13 08:01
Board/Management Information
Change of Broker
English 13.4 KB
2025-08-13 08:00
Regulatory News Service
Bulk Sample from Cusp and new prospect identified
English 68.4 KB
2025-07-30 08:00
Quarterly Report
Quarterly Report
English 121.8 KB
2025-07-24 08:00
Regulatory News Service
Harts Range delivers further HRE Mineralisation
English 38.5 KB

Automate Your Workflow. Get a real-time feed of all New Frontier Minerals Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for New Frontier Minerals Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for New Frontier Minerals Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.